Biokine Therapeutics News
6 articles
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications BioLineRx
BioLineRx Ltd., a clinical-stage biopharmaceutical company, has announced an agreement with Biokine Therapeutics to increase its stake in its lead oncology platform, BL-8040, from 60% to 80%. The transaction involves an upfront payment of $10 million in cash and $5 million in restricted BioLineRx shares, with Biokine also eligible to receive up to $5 million in future milestone payments. The $10 million upfront payment is being financed in full via the receipt of $10 million in debt financing from Kreos Capital. The transaction is expected to close within the next 10 days.
InvestmentAcquisition
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.
Partners
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.
Partners
BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML
BioLineRx has reported positive top-line results from its Phase 2 clinical trial for relapsed or refractory acute myeloid leukemia (AML). The company also identified a potential biomarker for future selection of BL-8040-responsive AML patients.
Customers
Cancer treatment co BioKine gets $1.2m grant
Biokine Therapeutics, Ltd. has received a $1.2 million research grant from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor. The funding will support a Phase I/IIa clinical study to test the safety and efficacy of the companys flagship product, cancer drug BKT140. The study has been initiated at the Sheba Medical Center. Biokine Therapeutics develops pharmaceuticals that control the activity of receptors for molecules called chemokines, which play a key role in the development of cancer and inflammatory diseases.
Investment
Cancer treatment co Biokine raises NIS 2.5m
Biokine, a developer of cancer treatment, has raised NIS 2.5 million in investment. The company is currently in the process of para-clinical trials for its cancer drug. Biokine was founded in 2000 by Dr. Amnon Peled and Dr. Lior Carmon. It has received research grants and funding from the EU sixth framework program. The companys cancer drug targets a receptor over-expressed in various types of cancer cells, causing them to die.
Investment
